1 Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous

- 2 cell carcinoma
- 3

4 AUTHORS AND AFFILIATIONS

- 5 Amarinder S. Thind^{1,2}, Bruce Ashford^{1,2,3}, Dario Strbenac⁴, Ruta Gupta⁵, Jonathan R Clark^{4,6,7},
- 6 N. Gopalakrishna Iyer⁸, Jenny Mitchell³, Jenny Lee^{9,10}, Simon A Mueller^{7,11}, Elahe Minaei^{2,12},
- 7 Jay R. Perry^{2,12} and Marie Ranson^{2,12}
- 8
- 9 ¹School of Medicine, University of Wollongong, Wollongong, NSW, Australia
- ²Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia
- ³Illawarra Shoalhaven Local Health District Wollongong, NSW, Australia,
- ⁴Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, NSW,
- 13 Australia
- ⁵Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
- ⁶Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District, Sydney, NSW,
- 16 Australia
- ¹⁷ ⁷Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Sydney, NSW, Australia
- 18 ⁸National Cancer Center, Singapore
- ⁹Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia
- ¹⁰Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia
- 21 ¹¹Department of Otorhinolaryngology, Head and Neck Surgery, Zurich University Hospital and
- 22 University of Zurich, Zurich, Switzerland
- ¹²School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW,
- 24 Australia
- 25

26 CORRESPONDENCE

- 27 A/Prof Bruce Ashford
- 28 bruceash@uow.edu.au
- 29 372 Crown St, Wollongong, New South Wales, Australia 2500
- 30 +61 2 42266111
- 31 Key words: whole genome sequencing, cutaneous squamous cell carcinoma, metastases, non-
- 32 coding mutations, UTR, cSCC
- 33

34 ABSTRACT

35 Metastatic cutaneous squamous cell carcinoma (cSCC) is a highly morbid disease requiring radical 36 surgery and adjuvant therapy that is associated with reduced overall survival. Yet compared to 37 other advanced malignancies, relatively little is known of the genomic landscape of metastatic 38 cSCC. We have previously reported the mutational signatures and mutational patterns of CCCTC-39 binding factor (CTCF) regions in metastatic cSCC. However, many other genomic components 40 (indel signatures, non-coding drivers, and structural variants) of metastatic cSCC have not been 41 reported. To this end, we performed whole genome sequencing on lymph node metastases and 42 blood DNA from 25 cSCC patients with regional metastases of the head and neck. We designed a 43 multifaceted computational analysis at the whole genome level to provide a more comprehensive 44 perspective of the genomic landscape of metastatic cSCC.

45

46 In the noncoding genome, 3'UTR regions of EVC (48% of specimens), PPP1R1A (48% of 47 specimens) and ABCA4 (20% of specimens) along with the tumor-suppressing lncRNA 48 LINC01003 (64% of specimens) were significantly functionally altered (Q-value < 0.05) and 49 represent potential noncoding biomarkers of cSCC. Recurrent copy number loss in the tumor 50 suppressor gene *PTPRD* was observed. Gene amplification was much less frequent and few genes 51 were recurrently amplified. Single nucleotide variants driver analyses from 3 tools confirmed TP53 52 and CDKN2A as recurrently mutated genes but also identified C9 as potential novel driver in this 53 disease. Further, indel signature analysis highlighted the dominance of ID signature 13 (ID13) 54 followed by ID8 and ID9. ID 9 has previously been shown to have no association with skin 55 melanoma, unlike ID 13 and 8, suggesting a novel pattern of indel variation in metastatic cSCC.

The enrichment analysis of various genetically altered candidates shows enrichment of 'TGF-beta regulation of extracellular matrix' and 'Cell cycle G1 to S check points'. These enriched terms are associated with genetic instability, cell proliferation, and migration providing mechanisms of genomic drivers of metastatic cSCC.

60 INTRODUCTION

61 Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy, after basal 62 cell carcinoma (BCC), affecting up to 1 000 000 people in the United States (US) annually [1]. In 63 time, and as a result of the ageing population and changing ratios of BCC/cSCC, the mortality rate 64 of cSCC is likely to exceed that of melanoma [2]. Although primary cSCC is common, metastasis 65 only occurs in 2-5% of cSCC [3-5]. cSCC arising in the head and neck generally show a predictable 66 pattern of spread, predominantly metastasizing to the intraparotid, level II (upper jugular) and 67 perifacial lymph nodes [4]. cSCC that have metastasized to regional lymph nodes are associated 68 with a worse prognosis [6], with modest progress made in the management of regionally advanced 69 disease over the last 15 years. Most patients with regional metastases from cSCC of the head and 70 neck are managed with a multimodality approach, which usually involves surgery (parotidectomy 71 and neck dissection) and adjuvant external beam radiotherapy depending on the site and stage at 72 the time of diagnosis [7-9]. More recently immunotherapy has attracted great interest as a potential 73 alternative for unresectable or distant metastatic disease [10, 11].

74

75 Despite the very high incidence, relatively little is known regarding the genomic landscape of 76 metastatic cSCC. We have previously described the genomic mutational burden, mutational 77 signatures, and mutations in CCCTC-binding factor regions using whole genome sequencing 78 (WGS) data from 15 cSCC metastases [12]. However, the majority of studies to date have reported

79 on somatic variation in primary cSCC [13-16] and/or cSCC metastases [16-20], using whole 80 exome sequencing (WES) and/or targeted next generation sequencing, which by definition 81 focusses on the coding genome. Thus, the extent of analysis of non-coding (including regulatory) 82 regions of the genome is limited and varies across studies. Pickering et al [20], the only study 83 employing WES, and incorporating 32 primary and only 7 metastatic samples, did not include 84 regulatory or non-exome regions analysis. Both Li et. al [18] (29 lymph node metastatic formalin 85 fixed paraffin embedded (FFPE) samples) and Zehir et. al [17] (MSK-IMPACT) (28 primary and 86 27 metastatic FFPE samples) used targeted NGS, with limited non-coding analysis. Zehir et al [17] 87 specifically included the TERT promoter in their targeted panels but otherwise included no 88 regulatory elements. Yilmaz et al. [16] performed WES and/or targeted NGS on 18 metastatic and 89 10 primary FFPE cSCC samples and reported coding gene drivers based purely on mutational 90 frequencies, without adjusting for gene length or covariates. Additional functional driver 91 predictions analysis would be required to confidently call genes as drivers [21]. Furthermore, FFPE 92 processing has well-known impacts on the quality of DNA for sequencing analyses [22] and it is 93 important to note that for most of the metastatic studies samples are collected using FFPE. Li et al 94 [18] similarly did not include regulatory or non-coding variant analysis. Furthermore, none of these 95 studies addressed variation in either 5' or 3' untranslated regions (UTR) or other non-coding 96 elements such as promoters (other than TERT promoter) or long non-coding RNAs. Sequence 97 variants occurring within these functional non-coding elements are important as they have the 98 potential to alter gene expression. For example, lncRNA are thought to influence expression of 99 proteins by pre- and post-translational influences on DNA/RNA and proteins, chromatin function, 100 miRNA activity and signaling pathways by an array of mechanisms [23, 24]. 3'UTRs regulate 101 crucial aspects of post-transcriptional gene regulation [25]. Mutations in these regions can

deregulate gene expression by disrupting miRNA-mRNA interactions, which in both tumor
 suppressor genes and oncogenes can drive cancer progression [26, 27]. This variation in so called
 cis-elements can also impact gene expression by altering translation initiation in cancer [28].

105

106 Given the shortcomings associated with WES and NGS analyses of complex genomes, in the 107 current report we have performed WGS on 25 metastatic cSCC samples and applied a detailed, 108 multifaceted computational analysis at the whole genome level to provide a comprehensive 109 understanding of the genomic landscape of metastatic cSCC. This included processing of WGS 110 data for somatic variations in both coding and non-coding regions, and indel signatures, apart from 111 structural variants and copy number alterations analyses. For non-coding genomic regions, we 112 have focussed on UTRs, lncRNA and promoters regions as these represent non-coding regions that 113 are most accessible to interrogation in high mutational burden tumours using currently available 114 tools.

115

116 MATERIALS AND METHODS

117 <u>Study population, sample collection and processing</u>

This study was undertaken with Institutional Human Research Ethics approval (UOW/ISLHD HREC14/397). Thirty-two patients with resectable metastatic cSCC (28 from males and 4 from females) were identified by the treating surgeons preoperatively. In addition to whole blood (for germline DNA), sections of fresh tumor from nodal metastases were collected during surgery and immediately snap frozen. These sections were used for both DNA/RNA extraction (Qiagen AllPrep, Qiagen, Hilden, Germany) and for cellularity estimates. Only samples with > 30% tumor (range 35-95%) proceeded to DNA quality control (QC). QC comprised spectrophotometry

125 (Nanodrop 2000 ThermoFisher Scientific Inc), gel-electrophoresis and SNP array. Of the 32 126 samples sequenced, 25 passed QC (96% from males) (Table 1). The remaining 7 samples had 127 insufficient clonal tumor content (median variant reads \leq 5 or median VAF < 0.1) or had an 128 extreme GC bias as determined by PURPLE [29]. Briefly, if more than 220 copy number segments 129 were unsupported by a corresponding structural variants at either end, the sample was flagged as 130 Fail-Segment. The mean sequencing coverage of the 25 samples was 94.56× (range: 64-143) for 131 tumor and 41.08× (range: 30-56) for blood.

132 Variant calling and functional significance of SNVs and indels

133 FASTQ reads were aligned to reference genome GRChr38 using BWA-kit version 0.7.17 (BWA-134 MEM read aligner) (for details refer to https://github.com/Sydney-Informatics-Hub/Fastq-to-135 BAM). The Genome Analysis Tool Kit (GATK) 4.1.2.0 and its BaseRecalibrator tool was used to 136 refine the read alignment. Single nucleotide polymorphisms (SNPs) and insertion-deletion (indel) 137 variants were called by implementing GATK's Best Practices Workflow. These pipelines use 138 HaplotypeCaller for germline short variant discovery and Mutech2 caller for somatic short variant 139 discovery for SNVs and Indels (for details refer to https://github.com/Sydney-Informatics-140 Hub/Somatic-ShortV). Furthermore, variants effect prediction and annotations were completed 141 using OpenCravat platform [30]. Mutation Annotation Format (MAF) files were generated based 142 with Variant Effect Predictor annotations. Three different methods for driver discovery were then 143 used; OncodriveFML[31], MutSigCV [21] and dNdScv [32].

144

OncodriveFML predicts the functional significance of both coding and non-coding variants as it is one of the few tools designed for non-coding genomic analysis [31]. It first determines the functional impact of the observed somatic mutations using Combined Annotation Dependent

Depletion (CADD) for specified genomic elements (UTR, promotor, coding regions) across the cohort. Later, for the statistical significance, it compares the average functional impact score of the observed mutations in the element with the average functional impact scores of a similar number of the random mutational set. The CADD score provides a priority for identifying mutations with functional, deleterious, and pathogenic impacts. These scores are calculated by combining the information from multiple annotations into a single metric.

154

MutSigCV identifies genes that are mutated more often than expected by chance and reduces the number of false positives in the generated list of significant genes, which is especially useful for tumors, such as metastatic cSCC, with high mutation rates [21]. This is achieved by incorporating various types of information such as patient-specific mutation frequencies and mutation spectra, gene-specific mutation rates, expression levels and replication times.

160

161 dNdScv is designed to test for positive and negative selection in cancer genomes [32]. As UV-162 induced cancer genomes such as cSCC can affect the accuracy of the dNdScv model we carefully 163 monitored the annotation of CC>TT changes (sometimes reported as C>T changes). Results report 164 significance for missense and truncating mutations, as well as indels as global p-values. Genes that 165 were falsely flagged as significant with negative selection were not considered for this analysis.

166

167 For downstream analysis, genes predicted to be driver genes by at least two of these tools were 168 considered. Firstly, genes with significance p-values <0.005 were filtered from each of the 3 tools, 169 and shared genes determined using a Venn diagram. We then compared the functional impact of 170 SNVs in these selected driver genes to previously reported primary and metastatic cSCC data [17,

171 18, 20, 33] available on cBioportal [34]. This included 92 samples of nodal metastatic cSCC
172 (WES= 10, targeted NGS = 82) and 88 samples of primary cSCC (WES=32, targeted NGS=56).

173 Copy Number Variation

174 Copy number alterations in the 25 metastatic genomes was derived using PURity & PLoidy 175 Estimator (PURPLE) [29], which estimates copy number and purity of tumor sample by using 176 read depth ratio from COBALT and tumor B-allele frequency (BAF) from AMBER. The pipeline 177 is available at github of HMF Tools (https://github.com/hartwigmedical/hmftools). Driver genes 178 with significant amplifications and deletions were then identified using PURPLE driver copy 179 number outputs. For driver genes, PURPLE searches for genes with high level amplification 180 (minimum Exonic Copy number > 3 * sample ploidy) and deletion (minimum exonic copy number 181 < 0.5) and then uses iteration to establish the most significant focal peaks.

182

183 GRIDSS2 and its companion interpreter tool LINX were employed for somatic structural variant
184 analysis and Gene fusion [35]. COSMIC3 based SNVs and Indels signatures from the whole
185 genome were built using MutationalPatterns [36] software, respectively.

186

187 The driver gene candidates obtained from various genetic alteration analyses such as copy number 188 variation drivers, somatic variant drivers, and other non-coding drivers were combined for 189 enrichment analysis. In the case of copy number gain/loss, we selected only those genes affected 190 in >20% of the samples in our cohort. Using the Enrichr web application [37] we determined the 191 involvement of the candidate driver genes in various cellular components of the cells, biological 192 pathways and predicted miRNA and drug targets.

193 **RESULTS**

194 Patient characteristics and clinicopathologic data

195 Twenty-five metastatic cSCC samples from lymph nodes in the head and neck region were 196 collected between 2015 and 2019 that passed WGS QC criteria for analysis (Table 1). The median 197 age of patients was 69 (range 30-87) and 24/25 (96%) were male. While this sex disparity is a 198 limitation of our study in that potential sex differences may have been missed, it is in keeping with 199 the disease burden seen in our practice in NSW, Australia, particularly for advanced and metastatic 200 cSCC (Ashford et al., manuscript under review). This is in keeping with findings that age, male 201 sex and immunosuppression are among the risk factors for metastasis [38]. Two patients were 202 immunocompromised; one patient was on long-term azathioprine for rheumatoid arthritis and the 203 other was on a combination of cyclophosphamide and tacrolimus following solid organ 204 transplantation.

205

The location of the index primary lesion was known in 11 patients (Table 1). Nodal metastases were isolated from the neck in 13 patients and in the parotid in 12 patients. The majority of patients had either moderately differentiated (n = 8) or poorly differentiated (n = 12) cSCC, with evidence of extranodal extension found in 20/25 (80%) nodal samples.

210 **Tumor mutational burden (TMB)**

Based on whole genome level calculations, the average TMB for SNVs and Indels across the 25 cases was 238.7 mutations per megabase (range 32.52 to 995.66 mutations/Mb) and 2.25 indel/megabase (range 0.63 to 5.9 mutations/Mb), respectively (Figure 1A, 1B; Supplementary Table 1) with the majority of somatic variants occurring in the non-coding regions as expected [12]. The only female tumor in this cohort had the second highest TMB at 499 mutations/Mb.

There was no correlation between age, differentiation, nodal stage or extracapsular spread of themetastasis and TMB.

218 Mutational signatures

219 We performed mutational signature analyses of the 25 genomes based on COSMIC V.3.2 220 (https://cancer.sanger.ac.uk/signatures/). Signatures are designated as single base substitution 221 (SBS), or small insertion and deletion (ID) signatures. SBS signatures 7a and 7b were the most 222 prevalent (Figure 1C; Supplementary Table 2) in keeping with a UV association in metastatic 223 cSCC as we previously reported in a smaller cohort using COSMIC V2 [12]. Substantial 224 representation of SBS7c was also seen. SBS32 and SBS7d were observed in one sample. Indel 225 signature analysis showed that ID8, 9 and 13 dominated over others (Figure 1D; Supplementary 226 Table 2).

227 Short variants

228 Coding Short Variants

229 The overwhelming majority of coding SNVs were missense mutations, followed by nonsense 230 mutation, which represented less than 5% of variants (Figure 2A). Figure 2B shows various DNA 231 sequence alterations, including single, double, and triple nucleotide variants as well as insertion 232 and deletion (Supplementary Data 1). Over 80% of SNVs were C>T (Figure 2C, 2D). This is 233 consistent with the dominant effect of UV radiation on pyrimidine bases and the UV signature 234 referred to above and is independent of the degree of differentiation or any other clinicopathologic 235 feature. Genes predicted to be driver genes via OncoDriveFML include TP53, CDKN2A and 236 ZNF730 having Q-values <0.1 (Figure 2E). MutSigCV and dNdScv analyses also found TP53 and 237 CDKN2A as the most significant mutated driver genes in our cohort (Supplementary Table 3). 238 Genes that were predicted to be driver genes (P-value < 0.005) by at least two tools were

- considered for downstream analyses (Figure 2F). This resulted in 12 genes; TP53, CDKN2A, C9,
- 240 C9orf131, SLC22A6, KHDRBS2, COLEC12, LINGO2, CDHR5, ZNF442, PRLR, and DHRS4. Of
- this list TP53, CDKN2A and C9 were shared as significant by all 3 tools. Interrogation of the
- cBioPortal dataset for cSCC (metastatic = 92 and primary=88 cases) [17, 18, 20] with short variant
- analysis (Supplementary Figure 1) revealed recurrent mutations in TP53, CDKN2A, but also C9,
- 244 COLEC12 and SLC22A6. Not all genes identified as high impact and recurrent variants in our
- 245 cohort were included in these targeted studies, which underscores the deficiencies of targeted 246 analyses in discovery projects.
- 247 The only sample with no mutation in *TP53* was CSCC 0009 (Figure 2G). The TMB of this sample
- 248 was 122/Mb, or 51% of the average across the cohort. Five samples without *CDKN2A* mutations
- averaged a TMB of 470/Mb, or 201% of the average for the cohort.
- 250 *Variation in non-coding regulatory regions*

The 3'UTRs that potentially play an important role in metastatic cSCC were discovered using OncodriveFML. SNVs within the 3'UTR region of *EVC*, *PPP1R1A*, *ABCA4*, and *LUM* showed significantly higher observed functional impact than the expected functional impact (Q-value <0.03) (Figure 3A, Supplementary Table 3). We observed variation within the 3'UTR of both *EVC* and *PPP1R1A* in 48% of samples with a Q-value of 0.011 and 0.022, respectively (Figure 3B; Supplementary Table 4). The unique *PPP1R1A* variant with cDNA change of c.*491C>T [Chr12:54579896 (G to A)] was found in 5 samples (Supplementary Figure 2).

- 259 There are many reported limitations in the analysis and interpretation of 5'UTRs and promoters
- for high mutational burden tumors [39-41], a finding we also observed (Supplementary Figure 3).

- 261 Currently no robust methodology exists to analyze these regions with confidence in cSCC thus 262 analyses of 5'UTRs and promoter regions were not investigated further.
- 263

264 IncRNAs likely to have a potential impact on tumorigenesis were also predicted using 265 OncodriveFML. Four IncRNAs were significantly (q < 0.05) biased towards high-impact 266 mutations i.e *LINC01474* and *LINC01003*, *RP4-597N16.4*, and *RP11-61J19.4* (Figure 3C; 267 Supplementary Table 3). Among these *LINC01474* and *LINC01003*, showed a high statistical 268 significance Q-value of 0.0158. IncRNA *LINC01003* was altered in 64% of the cohort. Other 269 recurrently mutated lncRNAs in our cohort was *RP11-61J19.4* (48% of samples) (Figure 3D; 270 Supplementary Table 4).

271 Structural and copy number variation

The extent of chromosomal copy number gain and loss was averaged across the genome for all 25 tumor samples (Figure 4A; Supplementary Table 5). Chr5p and 8q were the most frequently amplified regions, with 18q being the region with the most recurrent deletion. At sample level (Figure 4B), there were chromosome arm gains in Chromosome 7 and 5p in the majority of the samples and losses in 8p, 18q and 21q. Recurrent gain of 7, 8q, 5p and loss of 8p, 18, 21 was also previously reported by Pickering et al [20].

278

Structural variation analysis revealed that cSCC metastases are characterized by various complex, deleted, and unbalanced translocation events. Table 2 provides the summary of various structural events observed. Deletion and complex structural variants are common in cSCC; however, unbalanced translocation and other structural events were also observed (Table 2). The detailed effects of these structural events for putative oncogenes and tumor suppressor genes (TSG) are described in Table 3. Amplification events are linked to complex structural variants. Potential

285	oncogene/TSG driver amplification and deletion were predicted by the PURPLE-GRIDSS-LINX
286	pipeline, as reported in Table 3. Recurrent gene deletions were more common than gene
287	amplifications. The most frequently deleted gene was PTPRD (Chr9p, 24% of samples). PTPRD
288	deletion is already reported in primary and metastatic CSCC [42, 43]. Deletion of <i>PTPRD</i> (n=6)
289	and CDKN2A (Chr9p) (n=1) did not co-occur in our cohort (Table 3), although PTPRD loss and
290	significant mutation of CDKN2A co-occurred in 6 samples (CSCC_9, 11, 12, 133, 132 and 134)
291	(Table 3 and Figure 2G). Deep deletion of CDKN2A was reported in only 2/92 cases available on
292	cBioPortal (Supplementary Figure 1).

293

Loss of heterozygosity (LOH) was found at the focal, arm, chromosome, telomere, and centromere levels. The most common LOH events were that at the chromosome and arm level with these events concentrated to *PTPRD* locus (Table 3). No recurrent events for other genes among were observed (Table 3). Various examples of *PTPRD* structural events are reported in Supplementary Figure 4. A few other examples of the unbalanced translocation and complex structural variants are shown in Supplementary Figure 5.

300

The most frequently amplified genes (2/25, 8%) were *CALR*, *CCND1* and *FGF3* (Table 3). Interestingly *EGFR* was amplified in only one sample. Amplification of *CCDN1* and *FGF3* cooccurred in 2 samples (CSCC_0134 and CSCC_0132). *CCDN1* and *FGF3* are next to each other on the chromosome. These 2 cases had extensive nodal involvement (>50% of lymph nodes harboring tumor).

307 Despite this widespread genomic instability, only 2 coding-coding gene fusions were observed in 308 our cohort. The first was between STRN and DLG2 in sample CSCC 0009 (STRN: Exon 1 309 ENST00000263918 - DLG2 Exon 7 ENST00000376104). STRN encodes a calcium-dependent 310 calmodulin-binding protein [44]. DLG2 plays a role in pain signalling and deletion is seen in both 311 human and canine osteosarcoma [45]. We noted above that CSCC 0009 is the only sample without 312 TP53 mutations. CSCC 0009 came from a patient who had undergone liver transplantation and 313 was on immunosuppressive therapy. The primary tumor that gave rise to this metastasis showed 314 perineural involvement, which was also present in the metastatic deposit. The second gene fusion 315 was between NTRK2 and HEBP2 in CSCC 0011-M1. This seems to be caused by unbalanced 316 translocation event (Supplementary Figure 5.B).

317 Enrichment analysis

318 Gene enrichment analysis was performed using the 21 genetically altered candidates identified 319 above as significant/candidate driver genes, i.e., TP53, CDKN2A, C9, KHDRBS2, SLC22A6, 320 COLEC12, LINGO2, CDHR5, ZNF442, C9orf131, PRLR, DHRS4, PPP1R1A, EVC, LUM, 321 ABCA4, LINC01003, LINC01474 (RP11-151D14.1), RP4-597N16.4, RP11-61J19.4, and PTPRD. 322 The top significant pathway enrichment terms (Bio Planet 2019 [46]) are shown in Figure 5A. 323 Most of the significant Bioplanet enriched terms come from TP53 and CDKN2A, such as TP53 324 network, tumor suppressor ARF, CTCF pathway and cell cycle (G1/S checkpoint). However, 325 CDKN2A, LUM, CDHR5 and COLEC12 contribute to important cancer-related enrichment 326 pathways, such as 'TGF-beta regulation of extracellular matrix.' Full details of these enrichment 327 analyses are available in Supplementary Table 6.

328 The Jensen diseases enrichment tool identified skin cancer with highest significance (Figure 5B)

329 with Jensen compartment-based enrichment analysis showing that most of these genes belongs to

330 the extracellular compartment (Figure 5C). Other ontology enrichment analysis (MGI Mammalian 331 Phenotype Level 4 2021; Supplementary Table 6) showed enrichment of increased fibroblast 332 proliferation MP:0011703 where CDKN2A, TP53 and LUM alteration are the main contributors. 333 We also predicted the miRNA targets for these driver candidates (Figure 5D). hsa-miR-331-5p 334 was predicted to interact with 6 driver gene candidates, including TP53 and C9. For this prediction, 335 enricher platform use TargetScan miRNA database [47]. At the same time, hsa-miR-1181 was one 336 of the most significantly enriched miRNAs for these driver candidates, however can target only 2 337 driver genes.

338 **DISCUSSION**

339 This is the largest study to employ WGS to assess the mutational landscape of metastatic cSCC 340 and demonstrates the breadth of somatic variation across non-coding and coding regions. 341 Furthermore, we updated and expanded the understanding of UV-mutational signature patterns in 342 metastatic cSCC [12], including the identification of novel Indel (ID) signature patterns. This 343 highlights for the first time the nature and depth of variation within regulatory regions, with special 344 attention devoted to UTR, and lncRNA. Additionally, we reported various structural events at 345 whole genome scale for this diseases and also compared driver genes and SNVs to previous 346 WES/targeted NGS studies on metastasis cSCC.

347

At 238 mutations/Mb (Median of 166.99 mutations/Mb) (at whole genome scale), the rate of TMB within metastatic cSCC is substantially higher than other cancers known to have high mutational burden, including melanoma (49 mutations/Mb) [48]. This finding is in keeping with Pickering et al [20] who found a median of 61.2 mutations/Mb from their WES of high risk primary (n= 32)

and metastatic (n =7) cSCC being 4 times that of melanoma. The high TMB was associated with
 substantial structural variation, without recurrent gene fusions.

354

355 Alexandrov et al [49] detailed patterns of mutational signatures in 23829 tumor samples (1965 356 WGS) from the Pan Cancer Analysis of Whole Genomes (PCAWG) datasets including 17 small 357 ID signatures, expanded to 18 in COSMIC version 3.2 (https://cancer.sanger.ac.uk) [50]. However, 358 no cutaneous SCC (primary or metastatic) are included in this dataset. We identified the 359 predominance of ID signatures 8, 9 and 13 (100% of samples effected) in our 25 metastatic cSCC 360 samples. ID 8 is thought to be both related to double strand DNA break repair dysfunction and to 361 age related changes. Melanoma is the only other cancer type reported to have a predominant ID 362 13 signature [49]. Our data also provides evidence of concomitance of ID 13 with SBS 7a and 7b 363 (Figure 1C, 1D and Supplementary Table 2) in keeping with a UV-mediated mechanism for this 364 signature. While we found ID 9 to be a dominant indel signature in cSCC it is rare in melanoma 365 (2/104) but predominant in soft tissue sarcoma [49]. The mechanism of ID 9 is unclear but this 366 departure from what is found in melanoma clearly shows some point of difference in these UV-367 induced skin cancers. When comparing the TMB associated with ID 9 signature among different 368 cancers, the dominance in cSCC is clearly visible (Figure 6).

369

We identified substantial somatic variation within the 3'UTR region of *EVC*, *LUM* and *PPP1R1A*. *EVC* effects ciliary Hedgehog (Hh) regulation. Aberrant overexpression of *EVC* (and upregulation of Hh) has been reported in adult T-cell leukaemia as a result of epigenetic modulation [51]. The expression of *EVC* is reduced in nodal deposits of metastatic breast cancer compared with primary breast cancer suggesting a role in the metastatic process [52]. *PPP1R1A* is a protein phosphatase

inhibitor which appears to have a variable but significant role in the metastatic process. For example, it is overexpressed in Ewing Sarcoma, and has been proposed as a driver of metastasis [53]. Conversely, levels of *PPP1R1A* were reduced in breast cancer when compared to adjacent non-diseased breast tissue [54]. Within our cohort, we observed a unique recurrent missense mutation in the 3'UTR of *PPP1R1A* in 5 samples.

380

LINC01003 was the most mutated lncRNA in our cohort (64% of samples). In multiple myeloma, *LINC01003* behaves as a tumor suppressor genomic element. Up-regulation suppresses multiple myeloma by repressing cell viability and adhesion and promoting apoptosis. This effect is via its sponge effect on miR-33a-5p and its target *PIM1* [55].

385

386 As has been frequently reported for cSCC [5] (Supplementary Figure 1), TP53 and CDKN2A were 387 also the most recurrently altered genes in our cohort. Loss of function mutations within TP53 and 388 CDKN2A are well known to adversely impact cell cycle pathway control and DNA repair 389 mechanisms. Kilnakis et al [56] describe a pattern of TP53 mutation that differed between primary 390 and metastatic disease in head and neck (mucosal) SCC. They found an overall lower rate of 391 mutations in metastatic tumors, but a higher concentration of missense mutations in the DNA 392 binding regions of the gene. However, Yilmaz et al [16] reported a significantly higher TP53 393 mutation frequency in metastatic (85%) compared to primary tumors (corrected p-value < 0.002). 394 Additionally, they found a higher TMB with TP53 mutation, but a worse response to 395 immunotherapy. Burtness et al [57] reported that the extent of TMB in HPV-negative HNSCC is 396 associated with loss of function mutations in both TP53 and CDKN2A.

397 Of note in our study was the absence of significant or recurrent SNVs affecting *NOTCH1/2*. Inman 398 et al [14] compared well differentiated to moderately and poorly differentiated primary cSCC and 399 identified *NOTCH1*, *NOTCH2*, *TP53* and *CDKN2A* as the most commonly mutated genes, with 400 *ATP1A1*, *HERC6*, *MAPK1P1L*, *GRHL2*, *TRAPPC9*, *FLNB* and *MAP3K9* identified as common 401 early events in primary cSCC. Within this group, *GRHL2* was associated with less well 402 differentiated tumors including those with a worse prognosis. In our cohort, only a single splice 403 variant in *GRHL2* was identified, suggesting its role in metastatic disease is limited.

404 C9, (encodes complement component 9, C9) was also identified as a potential driver gene by 3 405 driver identification tools, with SNVs identified in 52% of the samples in our cohort. C9 is a part 406 of the membrane attack complex (MAC) and has been shown to modulate cellular behavior in the 407 tumor microenvironment (TME) [58]. Since the TME plays a crucial role in tumorigenesis, 408 progression, metastasis, and recurrence, C9 might have significant potential in cSCC progression 409 to metastasis. Various other components of the complement system have been linked to cSCC 410 progression and immunosuppression and implicated as potential therapeutic targets [59-61]. With 411 respect to C9 specifically, it appears to be recurrently mutated in cSCC specimens (31% in primary 412 and 10% in metastatic cSCC) as identified in the cBioPortal database (Supplementary Figure 1). 413 and high expression levels have been proposed as a potential biomarker for the detection of gastric 414 cancers [62] [63]. Further, the restrained expression of C9 in tumor-associated macrophages 415 promotes non-small cell lung cancer progression [64].

416

417 Apart from *TP53*, *CDKN2A* and *C9*, we identified 9 other potential driver genes with the most 418 recurrently mutated gene being *KHDRBS2* (48% of cohort) with various impacts, including stop 419 gained, complex and synonymous types apart from missense variant across the cohort. In the

420 cBioPortal database, this gene is mutated in 20% of metastatic cSCC specimens (Supplementary
421 Figure 1), suggesting it is a reasonably recurrently mutated gene in this disease.

422 Comparison of mutational frequency of primary and metastatic on the cBioPortal data suggests 423 the potential of COLEC12 (primary=25%; metastatic=60%) and SLC22A6 (primary=16%; 424 metastatic=30%) as a driver in metastatic cSCC (Supplementary Figure 1). Both COLEC12 and 425 SLC33A6 are mutated in 44% of the samples in our cohort, and many of them are high impact 426 SNVs. COLEC12 is involved in leukocyte recruitment and cancer metastasis [65], and regulates 427 the apoptosis of osteosarcoma [65]. Moreover, *COLEC12* is a potential biomarker of anaplastic 428 thyroid cancer (ATC) [66]. In one cancerous study of gastric stromal cells (GSCs), the role of 429 *COLEC12* is found in mediating the crosstalk between GSCs and dendritic cells (DCs) [67]. On 430 the other hand, SLC22A6 is known as an organic anion transporter 1 (OATI). Expression and 431 function alterations of OATI play an essential role in therapeutic efficacy and the toxicity of many 432 drugs. Such as for anti-cancer drugs methotrexate, Bleomycin, and Cisplatin-related toxicity [68-433 70]. OATI variation associated with cardiotoxicity in pediatric acute lymphoblastic leukemia and 434 osteosarcoma [71]. Furthermore, OAT1 role in Breast cancer metastasis has been reported [72]. 435 Important cancer-related roles of the other potential cSCC drivers are reported in Supplementary 436 Table 7.

437

Loss of *PTPRD* was the most prominent copy number alteration in our 25 samples. *PTPRD* encodes protein tyrosine phosphatase receptor D, which belongs to a family of receptors whose action oppose that of the tyrosine kinases, which are central to cell growth and differentiation and oncogenic transformation. Large scale genomic events impacting *CDKN2A* can also affect *PTPRD* due to their proximity on chr9 [73]. In head and neck SCC, *PTPRD* inactivation significantly

increases *STAT3* hyperactivation, which was associated with decreased survival and resistance to EGFR-targeted therapy [74]. *PTPRD* has been implicated as a tumor suppressor in several cancers with inactivating somatic variants found in >50% of GBM and between 10-20% of head and neck mucosal SCC (HNSCC) [75]. Lambert et al. [43] described deletions of *PTPRD* in 37% of metastatic primary cSCC and metastases. In addition, some of their cases also displayed a variant in the minor allele concordant with the deletion leading to a LOH event. It is thus possible that *PTPRD* plays a tumor suppressor role in preventing metastatic cSCC.

450

451 There were no recurrently amplified genes except for CALR, CCND1 and FGF3 which were each 452 only amplified in 2/25 samples (Table 3). CALR encodes a ubiquitous endoplasmic reticulum 453 bound calcium receptor [76]. Cellular stress can move CALR fragments to the plasma membrane 454 from the ER and influence immune recognition of cancer cells. Recent analysis of CALR fragments 455 in myeloproliferative disease suggest an immunosuppressive influence of extracellular CALR [77]. 456 Cyclin D1 (CCND1) amplification is associated with nodal metastasis and worse survival in oral 457 SCC [78]. In a review of *CCND1* copy number variation in metastatic non-cutaneous melanoma, 458 amplification was prominent in those patients whose disease did not respond to immune 459 checkpoint inhibition [79]. FGF3 amplification is more common in metastatic breast cancer than 460 primary tumors [80]. Targetable FGF3 amplification was associated with a poorer prognosis and 461 lung metastasis in hepatocellular carcinoma [81]. This amplification was seen in only 2% of total 462 HCC but was most common in those cancers showing rapid response to sorafenib.

463

With respect to enrichment of driver gene alterations observed in our samples, dysregulation of the cell cycle pathway appears to be the central genomic theme of metastatic cSCC supported 466 mainly by *TP53* and *CDKN2A*. *CDKN2A* encodes the CDK inhibitor p16^{INK4a}. This inhibitor is an 467 important controller of the activity of CDKs and progression from G1 to mitosis in the cell cycle. 468 Inactivating mutations in *CDKN2A* with effects on p16^{INK4a} regulatory functions uncouple cell 469 cycle control to promote tumorigenesis [82]. Interaction between *CDKN2A* and *TP53* through 470 *MDM2* and its regulation by ARF (also encoded by *CDKN2A*) further disable cell cycle and 471 apoptotic pathways (GO: Molecular function enrichment shows MDM2/MDM4 family protein 472 binding).

The cellular process defined by the term "TGF beta regulation of extra cellular matrix" was also significantly enriched showing a role for *LUM*, *CDHR5*, *COLEC12* and *CDKN2A* in this process (Figure 5A). TGF-beta modulates the deposition of the extracellular matrix (ECM) and affects cell proliferation, differentiation, and migration.

Finally, miR-331–5p shows promise as a potentiator of cSCC drivers. miR-331-5p downregulation contributes to chemotherapy resistance/relapse in leukemia [83] and it inhibits
proliferation by targeting PI3K/Akt and ERK1/2 pathways in colorectal cancer [84].

480 **CONCLUSION**

WGS provides insight into the unparalleled burden of mutation within metastatic cSCC, and our study has provided a deeper understanding of the genomic complexity of this disease. The functional impact of the varied and complex genetic alterations observed in metastatic cSCC should be validated in the future in confirmatory studies comparing whole genomes of nonmetastatic primary tumours to metastatic tumours. This would significantly contribute to the identification of biomarkers in primary cSCC for predicting metastasis.

488 **ACKNOWLEDGMENTS**

- 489 This work was funded by the Illawarra Cancer Carers, The Head and Neck Research Fund, Royal
- 490 Prince Alfred Institute of Academic Surgery, The Cancer Institute NSW translational program
- 491 grant, Chris O'Brien Lifehouse, National Health and Medical Research Council Project Grant
- 492 APP1181179 and Tour de Cure. Authors would like to acknowledge National Computational
- 493 Infrastructure (NCI-GADI) and Sydney Informatics Hub for computational services.

494

495 **CONFLICT OF INTEREST STATEMENT**

496 The authors state no conflict of interest.

497 **AUTHOR CONTRIBUTIONS STATEMENT**

498 AT performed the bioinformatics analyses and assisted in drafting the manuscript draft. BA 499 conceived the idea, assisted in bioinformatics analyses and drafted the manuscript. DS performed 500 bioinformatic analysis. MR assisted in drafting and editing the manuscript. BA and MR obtained 501 funding for the project. JM and RG collated clinical data. JP, EM completed tissue processing. JP, 502 EM, JC, RG, JL, SM reviewed and edited the manuscript.

503 DATA AVAILABILITY STATEMENT

504 The data files used for genomic analysis have been deposited at the European Genome-505 Phenome Archive, which is hosted by the EMBL-European Bioinformatics Institute and the 506 Center for Genomic Regulation, under accession number EGAS00001003370 507

Table 1. Clinicopathologic data of the cohort of 25 patients with cSCC lymph node metastases.

Sample		Primary location	Metastasis location	Immuno-suppressive treatment
	CSCC_0001	left lip	left neck	no
	CSCC_0002	right ear	right parotid	no
	CSCC_0003	unknown	right parotid	no
	CSCC_0004	bilateral lip	bilateral neck	no
	CSCC_0005	left forehead	left parotid	no
	CSCC_0006	left cheek	left neck	azathioprine
	CSCC_0007	unknown	left neck	no
	CSCC_0009	bilateral forehead	right neck	cyclosporine A, tacrolimus
	CSCC_0010	left scalp	left neck	no
	CSCC_0011	unknown	right parotid	no
	CSCC_0012	right nose	right neck	no
	CSCC_0013	right pinna	right parotid	no
	CSCC_0014	left cheek	left perifacial	no
	CSCC_0022	scalp	left neck	no
	CSCC_0024	lip	right neck	no
	CSCC_0025	parotid	Parotid	no
	CSCC_0066	Unknown	Parotid	no
	CSCC_0124	Parotid	Parotid	no
	CSCC_0125	parotid	parotid	no
	CSCC_0126	left temple	left neck	no
	CSCC_0130	unknown	left parotid	no
	CSCC_0132	right ear	parotid/neck	no
	CSCC_0133	unknown	parotid	no
	CSCC_0134	unknown	right neck	no
	CSCC_0135	unknown	right neck	no

Table 2: Summary of various event categories of structural variants. For more details, refer to Supplementary figures 4 and 5. Association can be noted between gain (Table 3) and complex SV events. The gene list was derived using LINX output. Only samples with events shown in Table.

Sample	SGL	Del	DUP	Complex	UNBAL_Trans	Pair.Other	INF
CSCC_0001	SMAD4	SMAD4					
CSCC_0002		CDKN2A					
CSCC_0005			МҮС	МҮС			
CSCC_0007				CRLF2			
CSCC_0009		PTPRD					
CSCC_0011		PTPRD		CALR	HEBP2- NTRK2		
CSCC_0012		PTPRD		EGFR		PTPRD	
CSCC_0013		APC					
CSCC_0014		CREBBP					CREBBP
CSCC_0025		CDKN2C			PARD6G		
CSCC_0066		PTPN13					
CSCC_0124		NEGR1				NEGR1	
CSCC_0132		PTPRD		RAF1-FGF3-CCND1			
CSCC_0133	PTPRD	PTPRD		CALR-chr1-chr3-chr6-chr8-chr22			
CSCC_0134				MCL1, CCND1-FGF3-Chr17			
CSCC_0135		PTPRD					

NBAL_TRANS - unbalanced translocation; **INF** = inferred breakend ; **DEL**=deletion; **DUP**=duplication; **SGL** = single breakend SV support

Table 3: List of reportable drivers (Likelihood Type Onco/TSG) genes. Types of drivers are: GAIN = amplification by SV; DEL= homozygous deletion; LOH = focal LOH; LOH_ARM = chromosome arm level LOH; LOH_CHR = chromosome level LOH; LOH_SV_TELO = LOH from SV to telomere; LOH_SV_CENTRO = LOH from SV to centromere. Only samples with events shown in Table.

Sample	DEL	GAIN	LOH_CHR	LOH_ARM	LOH	LOH_SV_TELO	LOH_SV_CENTRO
CSCC_0001	SMAD4					SMAD4	
CSCC_0002	CDKN2A						
CSCC_0003	KDM6A		KDM6A				
CSCC_0005		МҮС					
CSCC_0007		CRLF2					
CSCC_0009	PRPRD			PRPRD			
CSCC_0011	PRPRD	CALR		PRPRD			
CSCC_0012	PRPRD	EGFR	PPP2R3B,		PRPRD		
			PUDP,				
			STS,WWC3				
CSCC_0013	APC			APC			
CSCC_0014	CREBBP					CREBBP	
CSCC_0025	CDKN2C,		PARD6G	CDKN2C			
	PARD6G						
CSCC_0066	PTPN13		PTPN13				
CSCC_0124	NEGR1				NEGR1		
CSCC_0132	PRPRD	RAF1,CCND1,FGF3		PRPRD			
CSCC_0133	PRPRD	CALR					PRPRD
CSCC_0134		MCL1,CCND1,FGF3					
CSCC_0135	PRPRD			PRPRD			

26

FIGURES

Figure 1. Overview of tumor mutational burden and signatures (whole genome-based). (A, B) illustrate the indel and SNV mutational burden in each sample, respectively. (C, D) show Indel (ID) and SNV mutational signatures for each sample, respectively, obtained using COSMIC V3.2 database. Full details are available in Supplementary Table 2 (Tabs 2-4).



27

Figure 2. Overview of key coding mutations. (A) Variants classification, (B) variant types, (C) % transitions in all 25 samples and (D) % transitions for each sample. (E) Driver coding genes prediction results from OncodriveFML tool. The plot shows the most significantly altered genes (in the plots above the red line Q-values are below 0.1). Q-values are corrected P-values using the Benjamini/Hochberg correction (F) Venn diagram showing the overlap of genes predicted to be driver genes (P-value < 0.005) by 3 different driver detection tools, i.e. OncoDriveFML, MutSigCV and dNdScv. (For details refer to Supplementary Table 3). For further analysis, genes predicted to be driver genes by at least 2 tools were considered. (G) Detailed sample-level information of the SNVs along with types of variants in the top altered genes (from Figure 2F).



28

Figure 3. Driver genes prediction in non-coding genomic regions. Plots show the result of OncodrivFML (2.2.0) tool and mutations in the most significantly altered non-coding genes or regions in the cohort of 25 patient samples. (A) Potential 3'UTR regions associated driver candidates. (B) Variants with significantly altered 3'UTR regions. (C) Potential lncRNA driver's candidates. (D) Variants with significantly altered lncRNAs. Plots in (A) and (C) show the frequency of observed mutations with respect to the expected frequency of the mutations in the corresponding regions. Q-values are corrected P-values using the Benjamini/Hochberg correction.



29

Figure 4. Chromosomal and recurrent genetic copy number variation.(A) Combined chromosomal CNV across 25 metastatic cSCC samples at the chromosomal level. The X-axis represents the differences of mean minimum copy number (bands) and means of overall samples ploidy (after adjustment for purity). Refer to Supplementary Table 5. (B) Chromosomes arm loss and gain at the sample level (Red denotes a gain, and blue denotes a loss). Both arms of chromosomes 7 and 5p show gains. 8p, 18q, and 21q show loss. (A chromosome arm is defined to be deleted if at least half of its bases are one or more copies more than the sample ploidy.). Also shown is a Circos plot obtained from the PURPLE pipeline for CSCC_0004 as a representative example that summarizes various information at the sample level.



30

Figure 5. Enrichment analysis results of genetically mutated genes (21 candidates). (A) GO-Cellular Component terms showing 8 significantly enriched terms (obtained from BioPlanet 2019). (B) and (C) showing most significant Jensen diseases and Jensen compartments enriched terms, respectively. (D) Computationally predicted targets of miRNAs (TargetScan miRNA 2017). The x-axis represents the significance of the term. For details, refer to Supplementary Table 6.



31

Figure 6. Comparison plot of ID9 mutations for various cancers. cSCC shows the highest ID9 mutations per Mb. The bottom x-axis represents the cancer types, and the upper x-axis shows the number of samples measured for specific cancer types. Y-axis indicates the number of mutations per Mb. Data for other cancers was obtained from ID9 signature details from COSMIC V3.2 and compared with cSCC data. cSCC data is calculated as ID9 signature score/3100 (Coverage for hg38 genome).



32

REFERENCES

- 1. Rogers, H.W., et al., *Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012.* JAMA dermatology, 2015. **151**(10): p. 1081-1086.
- 2. Waldman, A. and C. Schmults, *Cutaneous Squamous Cell Carcinoma*. Hematol Oncol Clin North Am, 2019. **33**(1): p. 1-12.
- 3. Venables, Z.C., et al., *Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England.* JAMA dermatology, 2019. **155**(3): p. 298-306.
- 4. Forest, V.I., et al., *N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers.* Cancer: Interdisciplinary International Journal of the American Cancer Society, 2010. **116**(5): p. 1298-1304.
- 5. Ashford, B.G., et al., *Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets.* Head Neck, 2017. **39**(7): p. 1462-1469.
- 6. Mooney, C.P., et al., *The significance of regional metastasis location in head and neck cutaneous squamous cell carcinoma*. Head Neck, 2021. **43**(9): p. 2705-2711.
- 7. Veness, M.J., *Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma*. Australas Radiol, 2005. **49**(5): p. 365-76.
- 8. Garcia-Foncillas, J., et al., *Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma*. Cancers (Basel), 2022. **14**(3).
- 9. Stanganelli, I., et al., *The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.* Cancers (Basel), 2022. **14**(2).
- 10. Migden, M.R., et al., *PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma*. N Engl J Med, 2018. **379**(4): p. 341-351.
- 11. Aboul-Fettouh, N., et al., *Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma*. Dermatol Pract Concept, 2021. **11**(Suppl 2): p. e2021169S.
- 12. Mueller, S.A., et al., *Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma*. J Invest Dermatol, 2019. **139**(7): p. 1449-1458 e1.
- 13. Zilberg, C., et al., *Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma*. Modern Pathology, 2018. **31**(2): p. 275-287.
- 14. Inman, G.J., et al., *The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature*. Nat Commun, 2018. **9**(1): p. 3667.
- 15. Al-Rohil, R.N., et al., *Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.* Cancer, 2016. **122**(2): p. 249-57.
- 16. Yilmaz, A.S., et al., *Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors.* Cancer, 2017. **123**(7): p. 1184-1193.
- 17. Zehir, A., et al., *Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients*. Nature medicine, 2017. **23**(6): p. 703-713.
- 18. Li, Y.Y., et al., *Genomic analysis of metastatic cutaneous squamous cell carcinoma*. Clin Cancer Res, 2015. **21**(6): p. 1447-56.
- 19. Chang, D. and A.H. Shain, *The landscape of driver mutations in cutaneous squamous cell carcinoma*. NPJ Genom Med, 2021. **6**(1): p. 61.

- 20. Pickering, C.R., et al., *Mutational landscape of aggressive cutaneous squamous cell carcinoma*. Clin Cancer Res, 2014. **20**(24): p. 6582-92.
- 21. Lawrence, M.S., et al., *Mutational heterogeneity in cancer and the search for new cancerassociated genes.* Nature, 2013. **499**(7457): p. 214-218.
- 22. Hedegaard, J., et al., *Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.* PLoS One, 2014. **9**(5): p. e98187.
- 23. Statello, L., et al., *Author Correction: Gene regulation by long non-coding RNAs and its biological functions.* Nat Rev Mol Cell Biol, 2021. **22**(2): p. 159.
- 24. Cesana, M., et al., *A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA*. Cell, 2011. **147**(2): p. 358-69.
- 25. Barrett, L.W., S. Fletcher, and S.D. Wilton, *Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements*. Cellular and molecular life sciences, 2012. **69**(21): p. 3613-3634.
- 26. Liu, W. and X. Wang, *Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data*. Genome Biol, 2019. **20**(1): p. 18.
- 27. Schuster, S.L. and A.C. Hsieh, *The Untranslated Regions of mRNAs in Cancer*. Trends Cancer, 2019. **5**(4): p. 245-262.
- Kobayashi, H. and Y. Tomari, *RISC assembly: coordination between small RNAs and Argonaute proteins*. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2016. 1859(1): p. 71-81.
- 29. Priestley, P., et al., *Pan-cancer whole-genome analyses of metastatic solid tumours*. Nature, 2019. **575**(7781): p. 210-216.
- 30. Pagel, K.A., et al., *Integrated Informatics Analysis of Cancer-Related Variants*. JCO Clin Cancer Inform, 2020. **4**: p. 310-317.
- 31. Mularoni, L., et al., OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol, 2016. **17**(1): p. 128.
- 32. Martincorena, I., et al., Universal Patterns of Selection in Cancer and Somatic Tissues. Cell, 2017. **171**(5): p. 1029-1041.e21.
- 33. Gao, J., et al., *Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.* Sci Signal, 2013. **6**(269): p. pl1.
- 34. Cerami, E., et al., *The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.* Cancer Discov, 2012. **2**(5): p. 401-4.
- 35. Cameron, D.L., et al., *GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing.* Genome Biol, 2021. **22**(1): p. 202.
- 36. Blokzijl, F., et al., *MutationalPatterns: comprehensive genome-wide analysis of mutational processes*. Genome medicine, 2018. **10**(1): p. 1-11.
- 37. Kuleshov, M.V., et al., *Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.* Nucleic Acids Res, 2016. **44**(W1): p. W90-7.
- 38. Tokez, S., et al., *Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study.* J Am Acad Dermatol, 2021.
- 39. Mao, P., et al., *ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma*. Nat Commun, 2018. **9**(1): p. 2626.
- 40. Perera, D., et al., *Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes.* Nature, 2016. **532**(7598): p. 259-63.

- 41. Sabarinathan, R., et al., *Nucleotide excision repair is impaired by binding of transcription factors to DNA*. Nature, 2016. **532**(7598): p. 264-7.
- 42. Purdie, K.J., et al., Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol, 2009. **129**(6): p. 1562-8.
- 43. Lambert, S.R., et al., *Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.* Int J Cancer, 2012. **131**(3): p. E216-26.
- 44. Du, Q.Y., et al., *High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition.* Biomed Res Int, 2020. **2020**: p. 6152925.
- 45. Shao, Y.W., et al., Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma. Oncogene, 2019. **38**(2): p. 291-298.
- 46. Huang, R., et al., *The NCATS BioPlanet An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics.* Frontiers in Pharmacology, 2019. **10**.
- 47. Agarwal, V., et al., *Predicting effective microRNA target sites in mammalian mRNAs*. Elife, 2015.
 4.
- 48. Hayward, N.K., et al., *Whole-genome landscapes of major melanoma subtypes*. Nature, 2017. **545**(7653): p. 175-180.
- Alexandrov, L.B., et al., *The repertoire of mutational signatures in human cancer*. Nature, 2020.
 578(7793): p. 94-101.
- 50. Tate, J.G., et al., *COSMIC: the Catalogue Of Somatic Mutations In Cancer*. Nucleic Acids Res, 2019. **47**(D1): p. D941-d947.
- 51. Takahashi, R., et al., *Epigenetic deregulation of Ellis Van Creveld confers robust Hedgehog signaling in adult T-cell leukemia.* Cancer Sci, 2014. **105**(9): p. 1160-9.
- 52. Mamoor, S., *EVC is differentially expressed in lymph node metastasis in human breast cancer.* OSF Preprints, 2021.
- 53. Luo, W., et al., *Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.* Oncogene, 2018. **37**(6): p. 798-809.
- 54. Yuan, C.L., et al., *Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing.* BMC Cancer, 2019. **19**(1): p. 1171.
- 55. Wu, L., et al., Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis. Leuk Res, 2021. **106**: p. 106565.
- 56. Klinakis, A. and T. Rampias, *TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection*. EBioMedicine, 2020. **58**: p. 102905.
- 57. Burtness, B., et al., Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC). 2020, American Society of Clinical Oncology.
- 58. Zhang, R., et al., *Role of the complement system in the tumor microenvironment*. Cancer Cell Int, 2019. **19**: p. 300.
- 59. Rahmati Nezhad, P., et al., *Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma*. Cancers (Basel), 2022. **14**(2).
- 60. Johnson, E.M., et al., *Complement Factor H in cSCC: Evidence of a Link Between Sun Exposure and Immunosuppression in Skin Cancer Progression.* Front Oncol, 2022. **12**: p. 819580.
- 61. Riihila, P., et al., *Complement System in Cutaneous Squamous Cell Carcinoma*. Int J Mol Sci, 2019. **20**(14).

- 62. Chong, P.K., et al., *Upregulation of plasma C9 protein in gastric cancer patients*. Proteomics, 2010. **10**(18): p. 3210-21.
- 63. Joshi, V., et al., *Complement component C9 as a new biomarker for esophageal adenocarcinoma*. Journal of Clinical Oncology, 2017. **35**(4_suppl): p. 19-19.
- 64. Li, L., et al., Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression. Cell Death Discov, 2018. 4: p. 63.
- 65. Li, G.Z., et al., *COLEC12 regulates apoptosis of osteosarcoma through Toll-like receptor 4activated inflammation.* J Clin Lab Anal, 2020. **34**(11): p. e23469.
- 66. Espinal-Enríquez, J., et al., *Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma*. BMC Genomics, 2015. **16**(1): p. 207.
- 67. Chang, L.L., et al., *Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases.* Sci Rep, 2018. **8**(1): p. 3821.
- 68. Li, Q. and Y. Shu, *Role of solute carriers in response to anticancer drugs*. Mol Cell Ther, 2014.2: p. 15.
- 69. Sweet, D.H., Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol, 2005. **204**(3): p. 198-215.
- 70. Hu, S., et al., *Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity*. Clin Transl Sci, 2017. **10**(5): p. 412-420.
- 71. Sági, J.C., et al., *Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma*. BMC Cancer, 2018. **18**(1): p. 704.
- 72. Sutherland, R., A. Meeson, and S. Lowes, *Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis.* Cancer Metastasis Rev, 2020. **39**(3): p. 919-932.
- 73. Ortiz, B., et al., *Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis*. Oncotarget, 2014. **5**(16): p. 6976-82.
- 74. Veeriah, S., et al., *The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.* Proc Natl Acad Sci U S A, 2009. **106**(23): p. 9435-40.
- 75. Peyser, N.D., et al., *Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer*. PLoS One, 2015. **10**(8): p. e0135750.
- 76. Holmström, M.O., et al., *The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy*. Leukemia, 2018. **32**(2): p. 429-437.
- 77. Liu, P., et al., *Immunosuppression by Mutated Calreticulin Released from Malignant Cells*. Mol Cell, 2020. **77**(4): p. 748-760.e9.
- 78. Miyamoto, R., et al., *Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas*. Oral Oncol, 2003. **39**(6): p. 610-8.
- Yu, J., et al., Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clin Cancer Res, 2019. 25(21): p. 6511-6523.
- 80. Rinaldi, J., et al., *The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors.* PLoS One, 2020. **15**(5): p. e0231999.
- 81. Arao, T., et al., *FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma*. Hepatology, 2013. **57**(4): p. 1407-15.

- 82. Zhao, R., et al., *Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer*. EBioMedicine, 2016. **8**: p. 30-39.
- 83. Feng, D.D., et al., *Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.* J Cell Mol Med, 2011. **15**(10): p. 2164-75.
- 84. Zhao, D., Y. Sui, and X. Zheng, *MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer*. Oncol Rep, 2016. **35**(2): p. 1075-82.